GW & Wade’s Teva Pharmaceuticals TEVA Stock Holding History

GW & Wade’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-3,130	Closed	-$205K	–	225
2015 Q4	$205K	Buy	+3,130	New	+$193K	0.04%	198
2015 Q2	–	Sell	-91,376	Closed	-$5.69M	–	242
2015 Q1	$5.69M	Sell	91,376 -13,198	-13%	-$767K	1.07%	24
2014 Q4	$6.01M	Sell	104,574 -947	-0.9%	-$52.8K	1.58%	18
2014 Q3	$5.67M	Buy	105,521 +31,875	+43%	+$1.69M	1.65%	17
2014 Q2	$3.86M	Buy	73,646 +17,006	+30%	+$869K	1.14%	31
2014 Q1	$2.99M	Buy	+56,640	New	+$2.62M	0.97%	38

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

GW & Wade's TEVA Position: Q1 2016 in Review

GW & Wade sold out of Teva Pharmaceuticals (TEVA) in Q1 2016, closing a stake of 3,130 shares — an estimated $205K sold.

GW & Wade first reported a position in TEVA in Q1 2014 and held it in 6 quarters. The position peaked at $6.01M in Q4 2014. 836 funds tracked by Wall St. Rank hold TEVA as of Q1 2016.

GW & Wade reported no remaining Teva Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
GW & Wade sold 3,130 Teva Pharmaceuticals shares in Q1 2016, an estimated $205K.
GW & Wade first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 6 quarters.
GW & Wade's Teva Pharmaceuticals position peaked at $6.01M in Q4 2014.
836 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2016.

Based on GW & Wade's 13F filing for Q1 2016, filed 26 Apr 2016.